Advanced in Osteosarcoma

Dr. Santhosh Upadhyaya

Hematology | Oncology
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Osteosarcoma
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Santhosh Upadhyaya is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Upadhyaya is rated as an Advanced provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Rhabdoid Tumor, Teratoma of the Mediastinum, Glioma, Medulloblastoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI 48109
Other Locations
St. Jude Children's Research Hospital
262 Danny Thomas Pl, Memphis, TN 38105

Additional Areas of Focus

Dr. Upadhyaya has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Enrollment Status: Recruiting
Publish Date: January 07, 2026
Intervention Type: Drug, Procedure, Biological, Radiation, Other
Study Drugs: Carboplatin, Etoposide, Filgrastim, Ifosfamide, Mesna, Pegfilgrastim, Thiotepa
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Alisertib, Methotrexate, Cisplatin, Carboplatin, Cyclophosphamide, Etoposide, Topotecan, Vincristine
Study Phase: Phase 2
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine
Study Phase: Phase 2
View 5 Less Clinical Trials

37 Total Publications

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.
Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.
Journal: Physical review letters
Published: October 30, 2024
Similar Doctors
Elite in Osteosarcoma
Dr. Patrick Grohar
Hematology | Oncology
Elite in Osteosarcoma
Dr. Patrick Grohar
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (0.4 miles away)
734-936-4000
Languages Spoken:
English

Patrick Grohar is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Grohar is rated as a Distinguished provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Rhabdoid Tumor.

Elite in Osteosarcoma
Dr. Rashmi Chugh
Oncology | Hematology
Elite in Osteosarcoma
Dr. Rashmi Chugh
Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (0.1 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rashmi Chugh is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Chugh is rated as an Elite provider by MediFind in the treatment of Osteosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma.

Distinguished in Osteosarcoma
Dr. Scott Schuetze
Oncology
Distinguished in Osteosarcoma
Dr. Scott Schuetze
Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (0.1 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Schuetze is an Oncologist in Ann Arbor, Michigan. Dr. Schuetze is rated as an Elite provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Upadhyaya's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile